|
000
| 02215nam 2200373zi 4500 |
|---|
| 001 | 9.919396 |
|---|
| 003 | CaOODSP |
|---|
| 005 | 20230302165704 |
|---|
| 006 | m o d f |
|---|
| 007 | cr mn||||||||| |
|---|
| 008 | 230124e202302##oncd ob f000 0 eng d |
|---|
| 020 | |a9780660472331 |
|---|
| 040 | |aCaOODSP|beng|erda|cCaOODSP |
|---|
| 043 | |an-cn--- |
|---|
| 086 | 1 |aHP5-154/2023E-PDF |
|---|
| 245 | 00|aRecommendations on the use of conjugate pneumococcal vaccine - 15 valent (PNEU-C-15) and 20 valent (PNEU-C-20) in adults : |beconomic evidence supplementary appendix. |
|---|
| 264 | 1|aOttawa, ON : |bPublic Health Agency of Canada = Agence de la santé publique du Canada, |cFebruary 2023. |
|---|
| 264 | 4|c©2023 |
|---|
| 300 | |a1 online resource (44 pages) : |bgraphs |
|---|
| 336 | |atext|btxt|2rdacontent |
|---|
| 337 | |acomputer|bc|2rdamedia |
|---|
| 338 | |aonline resource|bcr|2rdacarrier |
|---|
| 500 | |aIssued also in French under title: Recommandations sur l'utilisation du vaccin conjugué 15-valent (PNEU-C-15) contre le pneumocoque et 20-valent (PNEU-C-20) contre le pneumocoque chez les adultes : annexe de données économiques supplémentaires. |
|---|
| 500 | |aOn cover: An advisory committee statement (ACS), National Advisory Committee on Immunization (NACI). |
|---|
| 500 | |a"Pub.: 220714." |
|---|
| 504 | |aIncludes bibliographical references (pages 38-44). |
|---|
| 650 | 0|aPneumococcal vaccine|zCanada. |
|---|
| 650 | 0|aVaccines|xEconomic aspects|zCanada. |
|---|
| 710 | 2 |aPublic Health Agency of Canada, |eissuing body. |
|---|
| 710 | 1 |aCanada. |bNational Advisory Committee on Immunization, |eissuing body. |
|---|
| 775 | 08|tRecommandations sur l'utilisation du vaccin conjugué 15-valent (PNEU-C-15) contre le pneumocoque et 20-valent (PNEU-C-20) contre le pneumocoque chez les adultes : |w(CaOODSP)9.919397 |
|---|
| 856 | 40|qPDF|s1.87 MB|uhttps://publications.gc.ca/collections/collection_2023/aspc-phac/HP5-154-2023-eng.pdf |
|---|
| 856 | 4 |qHTML|sN/A|uhttps://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/public-health-level-recommendations-use-pneumococcal-vaccines-adults-including-use-15-valent-20-valent-conjugate-vaccines/economic-evidence-supplementary-appendix.html |
|---|